Overview

The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A pilot study to investigate the potential role of atosiban, a selective oxytocin receptor inhibitor, in the management of endometriosis-related pain. Ten patients will be administered atosiban intravenously during 6 hours on a day during their period when they experience (severe) pain
Phase:
Phase 2
Details
Lead Sponsor:
Radboud University Medical Center
Treatments:
Atosiban